Nasdaq · Healthcare
KYNTRA BIO, INC. (KYNB)
As-reported financials and recent SEC filings for KYNTRA BIO, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$6.4M
Net income
$183.5M
Net margin
—
Diluted EPS
$45.37
ROE
-1078.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.4M | $29.6M | $46.8M | $140.7M | $235.3M |
| Gross profit | $5.9M | $14.1M | $42.8M | $120.5M | — |
| Operating income | $-45.9M | $-150.4M | $-322.7M | $-301.0M | $-288.5M |
| Net income | $183.5M | $-47.6M | $-284.2M | $-293.7M | $-290.0M |
| Diluted EPS | $45.37 | $-11.89 | $-70.08 | $-75.36 | $-75.36 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →8-K2026-06-09
View on EDGAR →Largest Healthcare peers
Go deeper on KYNB
Search KYNTRA BIO, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.